13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.

      1 , 1 , 1 , 2 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 1 , 9 , 10 , 11 , 2 , 12 , 13 , 14 , 15 , 4 , 16 , 17 , 1 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 2 , 29 , 30 , 31 , 32
      The Lancet. Oncology
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab showed improved outcomes for patients with metastatic colorectal cancer, compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab. However, the actual benefit of the upfront exposure to the three cytotoxic drugs compared with a preplanned sequential strategy of doublets was not clear, and neither was the feasibility or efficacy of therapies after disease progression. We aimed to compare a preplanned strategy of upfront FOLFOXIRI followed by the reintroduction of the same regimen after disease progression versus a sequence of mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) and FOLFIRI doublets, in combination with bevacizumab.

          Related collections

          Author and article information

          Journal
          Lancet Oncol
          The Lancet. Oncology
          Elsevier BV
          1474-5488
          1470-2045
          April 2020
          : 21
          : 4
          Affiliations
          [1 ] Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
          [2 ] Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, IRCCS, Padua, Italy.
          [3 ] Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy; Oncology and Hemato-oncology Department, Università degli Studi di Milano, Milan, Italy.
          [4 ] Medical Oncology Unit, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione, Garibaldi Catania, Catania, Italy.
          [5 ] Oncology Unit, Foundation IRCCS, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
          [6 ] Oncology Unit, Ospedale degli Infermi, Rimini, Italy; Department of Oncology and Palliative Care, Cardinale G Panico, Tricase City Hospital, Tricase, Italy.
          [7 ] Department of Medical Oncology, University Campus Biomedico, Rome, Italy.
          [8 ] Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy.
          [9 ] Department of Medical Oncology, F Spaziani Hospital, Lazio, Italy.
          [10 ] Department of Oncology, University and General Hospital, Udine, Italy; Department of Oncology, San Bortolo General Hospital, Vicenza, Italy.
          [11 ] Medical Oncology Unit, Poliambulanza Foundation, Brescia, Italy.
          [12 ] Department of Oncology, S Croce and Carle Teaching Hospital, Cuneo, Italy.
          [13 ] Department of Medical Oncology, IRCCS, Centro di Riferimento Oncologico National Cancer Institute, Aviano, Italy.
          [14 ] Department of Oncology, University Hospital of Pisa, Pisa, Italy.
          [15 ] Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
          [16 ] Medical Oncology Unit, Careggi University Hospital, Florence, Italy.
          [17 ] Medical Oncology Unit, Azienda Socio-Sanitaria Territoriale of Cremona, Cremona Hospital, Cremona, Italy.
          [18 ] Department of Oncology, Hospital San Raffaele, IRCCS, Milan, Italy.
          [19 ] Department of Medical Oncology, General Hospital, Prato, Italy.
          [20 ] Department of Clinical Medicine and Surgery, University Federico II, Napoli, Italy.
          [21 ] Medical Oncology Unit, Ente Ospedaliero Ospedali Galliera, Genoa, Italy.
          [22 ] Struttura Semplice Dipartimentale, ColoRectal Cancer Unit, Department of Oncology, Azienda Ospedaliero-Universitaria, Città della Salute e della Scienza di Torino, Turin, Italy.
          [23 ] Oncological Department, Azienda UnitàSanitaria Locale, Toscana Nord Ovest, Oncological Unit of Massa Carrara, Carrara, Italy.
          [24 ] Department of Systems Medicine, Medical Oncology Unit, Tor Vergata University, Rome, Italy.
          [25 ] Department of Oncology, Division of Medical Oncology, Azienda Toscana Nord Ovest, Livorno, Italy.
          [26 ] Medical Oncology, IRCCS, Ospedale San Martino Istituto Scientifico Tumori, Genoa, Italy.
          [27 ] Department of Medical Oncology, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia, IRCCS, Candiolo, Italy.
          [28 ] Unit of Medical Oncology, Ospedale Santa Maria della Misericordia, Perugia, Italy.
          [29 ] Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
          [30 ] Department of Laboratory, Pathology section, University Hospital of Pisa, Pisa, Italy.
          [31 ] Clinical Trials Coordinating Center, Toscano Cancer Institute, University Hospital Careggi, Florence, Italy.
          [32 ] Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy. Electronic address: alfredo.falcone@med.unipi.it.
          Article
          S1470-2045(19)30862-9
          10.1016/S1470-2045(19)30862-9
          32164906
          5648c2a8-51f0-422a-a80c-a1245bced6c1
          Copyright © 2020 Elsevier Ltd. All rights reserved.
          History

          Comments

          Comment on this article